ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR
Tibsovo is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory acute myeloid leukemia (AML) that has tested positive for a mutation in the isocitrate dehydrogenase-1 (IDH1) gene. Tibsovo may also be referred to by its drug name, ivosidenib.
Tibsovo is the first drug in a class called IDH1 inhibitors. Tibsovo is believed to work by interfering with the ability of leukemia cells to release stored energy.
How do I take it?
Tibsovo is taken orally once a day.
Tibsovo comes in the form of a tablet.
The FDA-approved label for Tibsovo lists common side effects including fatigue, fever, cough, rash, joint pain, mouth sores, nausea, diarrhea, constipation, trouble breathing, and swelling.
Rare but serious side effects listed for Tibsovo include fetal harm in pregnant people and differentiation syndrome, a life-threatening condition that causes trouble breathing and hypotension (low blood pressure). Tibsovo can also cause changes in heart rhythm and Guillain-Barré Syndrome, a condition in which the immune system attacks the nerves, causing weakness and potentially fatal paralysis of the muscles needed for breathing.
For more details about this treatment, visit:
Tibsovo — Agios
AML: Relapsed and Refractory — Leukemia and Lymphoma Society